Por favor, use este identificador para citar o enlazar este ítem:
https://www.arca.fiocruz.br/handle/icict/30154
Tipo
ArtículoDerechos de autor
Acceso restringido
Fecha del embargo
2025-08-30
Colecciones
- INI - Artigos de Periódicos [3397]
Metadatos
Mostrar el registro completo del ítem
CLINICAL USE OF RALTEGRAVIR: A REVIEW
Afiliación
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Laboratório de Pesquisa Clínica em DST/AIDS. Rio de Janeiro, RJ, Brasil.
Resumen en ingles
In the last 5 years there have been important achievements in the field of HIV therapy with the availability of new
classes of antiretrovirals together with a new generation of old classes. Among them, the development of raltegravir,
the first commercially available component of integrase inhibitors, brought an extraordinary improvement in salvage
therapy for HIV-infected patients, allowing for virologic suppression even in multi-experienced subjects, who until
recently had limited treatment options. It was subsequently approved for initial treatment combined with a
nucleoside/nucleotide backbone, and also became an interesting option for naive HIV-infected populations. Its
unique characteristics, the limited potential for significant pharmacokinetic interactions with other drugs and
excellent safety profile have increased interest in its use in different settings.
Compartir